drugset / Trial / NCT00150735

Monotherapy With Levetiracetam in Newly Diagnosed Patients Suffering From Epilepsy

NCT00150735

Phase 3 Completed 580 enrolled UCB Pharma
Non-randomizedParallel-groupDouble-blind

Summary

A double-blind trial comparing the efficacy and safety of levetiracetam to carbamazepine used as monotherapy in subjects (≥ 16 years) newly or recently diagnosed as suffering from epilepsy, and experiencing partial or generalized tonic-clonic seizures.

Timeline

Start
2002-06
Primary completion
2005-07
Completion
2005-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Levetiracetam Other / unclassified 1000 mg Oral
Subject Levetiracetam Other / unclassified 3000 mg Oral

Indications